Colorado Cannabis Market Nears $19 Billion in Lifetime Revenue, New Report Shows

Colorado cannabis market peaked in 2021, with revenue of roughly $2.24 billion, and has been declining since to approximately $1.32 billion in 2025. However, the market has not yet found the floor.

That’s according to a new market review by Emerald Intel, titled Colorado Cannabis Market: 2014–2026 Performance Review. The authors took a closer look at Colorado cannabis sales, patient registration, retail licensing, and product mix from 2014 through June 2026.

In the first half of 2026, revenue came in at about $633.5 million. The report suggests the correction took longer than a typical post-peak reset, a trend that could point to gradual market stabilization rather than a sharp rebound.

That said, Colorado has generated around $18.9 billion in cumulative cannabis revenue over the 12 years since becoming the first jurisdiction in the world to launch legal, commercial recreational marijuana sales for adults 21 and older. Out of that sum, cumulative recreational cannabis sales accounted for $15 billion, while the remainder of $3.97 billion was medical marijuana sales.

Medical cannabis, which has been available in the Centennial State since 2010 following the implementation of a 2009 state law, fell from 55.6% of monthly revenue in 2014 to about 8.6% in the first half of 2026.

As of June 2026, Colorado boasted 757 active licensed stores where roughly 51,400 active registered medical cannabis patients have been purchasing cannabis. That’s a decrease from a 2011 peak of 127,816 active registered medical cannabis patients, according to the report’s retail analysis.

By mid-2026, flower’s revenue share had dropped to 38% of monthly revenue from about 50.1% in 2018. Concentrates accounted for roughly 41%–43% of recent monthly revenue, while edibles were steady at around 14%–15%.

Outlook

Going forward, Colorado’s cannabis market could be reshaped by several developments in addition to declining sales, as pointed out by the report. 

Consolidation is one of the major themes in the mature cannabis market, such as Colorado. The report said, “retail consolidation is proceeding through the open market, not a licensing ceiling,” referring to an anticipated acquisition of 17 of 21 Native Roots dispensaries by Verdant Capital Partners. Announced in March 2026, the acquisition of one of the state’s oldest and largest chains follows a December 2025 executive order directing federal agencies to work toward rescheduling cannabis to Schedule III.

Separately, Vireo Growth Inc. announced in March the closing of its previously disclosed acquisition of certain assets of U.S. multistate cannabis operator Medicine Man Technologies Inc., doing business as Schwazze. According to its press release, that deal included 24 dispensaries in Colorado, 21 dispensaries in New Mexico, and one manufacturing facility in each state. In August, Vireo completed another Colorado deal – its approximately $49 million acquisition of 17 PharmaCann dispensaries.

Another point of pressure is wholesale reporting and tax compliance. Colorado’s Marijuana Enforcement Division (MED) and representatives of the industry have raised concerns over widespread wholesale transaction misreporting in METRC. MED highlighted “thousands of suspicious entries” appearing in the state’s seed-to-sale tracking system, with some transactions reportedly recorded at values well below typical market levels. The report warned that both tax collections and reported wholesale activity could be understated.

Furthermore, in anticipation of federal restrictions on hemp, the report flagged hemp-derived products as a competitive and regulatory risk. MED announced plans to crack down on cannabis businesses using chemically converted hemp-derived THC this past April.

The report also pointed to local licensing changes in Denver as a market mover to watch closely as designated sunset date of July 1, 2027, for the city’s social-equity licensing program.